Publications by authors named "M A Mayoux"
Article Synopsis
- Multiple myeloma (MM) is still an incurable cancer despite available therapies, with T-cell bispecific antibodies (TCBs) targeting BCMA and GPRC5D showing promise but facing issues like resistance and relapse due to antigen loss.
- Forimtamig is a novel GPRC5D-targeting TCB that works more effectively than traditional formats by forming stable immunological connections, leading to better tumor cell destruction and T cell activation in preclinical studies.
- Current research is exploring forimtamig in clinical trials for relapsed and refractory MM patients, both alone and alongside traditional care and new therapies, to enhance treatment outcomes and prevent relapses.
Group 1 innate lymphoid cells (ILCs) comprising circulating natural killer (cNK) cells and tissue-resident ILC1s are critical for host defense against pathogens and tumors. Despite a growing understanding of their role in homeostasis and disease, the ontogeny of group 1 ILCs remains largely unknown. Here, we used fate mapping and single-cell transcriptomics to comprehensively investigate the origin and turnover of murine group 1 ILCs.
View Article and Find Full Text PDFAging exerts profound and paradoxical effects on the immune system, at once impairing proliferation, cytotoxicity and phagocytosis, and inducing chronic inflammation. Previous studies have focused on individual tissues or cell types, while a comprehensive multisystem study of tissue-resident and circulating immune populations during aging is lacking. Here we reveal an atlas of age-related changes in the abundance and phenotype of immune cell populations across 12 mouse tissues.
View Article and Find Full Text PDFArticle Synopsis
- PD-L1/PD-1 blocking antibodies have shown effectiveness in treating various cancers, but there is a need for more research to maximize their benefits for patients.
- The study highlights that dendritic cells (DCs) are significant targets of PD-L1 blocking antibodies, not just T cells, as PD-L1 binding affects their ability to activate T cells.
- In patients with specific cancers, those treated with PD-L1 blockers like atezolizumab showed a gene signature in DCs linked to better survival rates, indicating that this treatment enhances the immune response against cancer.